Amgen wants Wegovy-like drug that can be tapered down

Amgen is testing their obesity drug candidate, MariTide, to see if they can wean patients toward lower doses over time. Very early data suggests that MariTide may provide longer-lasting weight loss than other popular obesity drugs and could potentially be taken less frequently. Amgen’s unique strategy is to transition patients to a less intensive dosing regimen and to see if they can maintain weight loss even after stopping the drug. The drug also has a unique mechanism and researchers are considering the possibility that it may be taken monthly for maintenance. Researchers are intrigued by the results and are looking into developing longer-lasting treatments for obesity.

Source link